Skip to main content

Table 4 OS prognostic score in the FAS and the FAS CORRECT populations

From: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program

FAS Population n = 654   Median OS 6-month OS rate
 Score equal to 0,1, 2, or 3 (high benefit from REG, n = 213) 1 9.2 67 %
 Score equal to 4 or 5 (moderate benefit from REG, n = 256) 1.78 (1.45–2.18) 5.2 45 %
 Score equal to 6+ (low benefit from REG, n = 147) 2.70 (2.13–3.42) 2.5 26 %
FAS-CORRECT Population n =440
 Score equal to 0 or 1 (high benefit from REG, n = 185) 1 8.7 64 %
 Score equal to 2 (moderate benefit from REG, n = 206) 1.67 (1.34–2.09) 5.5 46 %
 Score equal to 3 (low benefit from REG, n = 48) 2.54 (1.79–3.60) 3.4 35 %
  1. Relative weights of the variables found independently related to survival (see Table 3) were added to obtain a total score. This score ranged from 0 to 10, and was then reduced to obtain three categories of patients with significantly different risks of death